Predictmedix Announces Closing of Private Placement
Predictmedix Announces Closing of Private Placement
TORONTO, ON / ACCESSWIRE / June 21, 2023 / Predictmedix Inc. ("Predictmedix" or the "Company") (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI), announces the closing of its previously announced private placement. The Company has issued 10,510,000 units (the "Units") at a price of $0.10 per unit to investors for gross proceeds of $1,051,000. Each Unit consists of one common share of the Company and one common share purchase warrant (a "Warrant"), whereby each Warrant entitles the holder to purchase one additional common share for a period of two years from closing at an exercise price of $0.15 per share.
多倫多,2023年6月21日/ACCESSWIRE/由專有人工智慧(AI)支持的快速健康篩查解決方案的領先提供商Predidicmedix Inc.(以下稱PredicicMedix或公司)(CSE:PMEd)(場外交易市場代碼:PMEDF)(FRA:3QP)宣佈結束其先前宣佈的定向增發。本公司已按每單位0.10美元的價格向投資者發行10,510,000個單位(“單位”),總收益為1,051,000美元。每個單位包括一股本公司普通股和一份普通股認購權證(“認股權證”),據此,每份認股權證持有人有權在兩年內以每股0.15美元的行使價購買額外一股普通股。
The net proceeds from the private placement will be primarily allocated towards general operations, focusing on working capital requirements, which includes essential aspects such as business development and technology upgrades. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the date of issuance of the securities. This funding infusion will enable Predictmedix to expand its operations, invest in research and development, and enhance its product offerings, ultimately strengthening its position as a leading provider of AI-driven health screening solutions.
私募的淨收益將主要分配給一般業務,重點是營運資金需求,其中包括業務發展和技術升級等基本方面。所有與私人配售有關而發行的證券,均須受自證券發行日期起計四個月零一天的法定持有期所規限。這筆資金注入將使Predidicmedix能夠擴大其業務,投資於研發,並增強其產品供應,最終加強其作為人工智慧驅動的健康篩查解決方案領先提供商的地位。
"We are thrilled to have successfully concluded our private placement, which highlights the confidence and support we have received from our investors. This additional capital will fuel our ongoing efforts to revolutionize health screening through the power of artificial intelligence. With these funds, we will further develop our technology, expand our operations, and drive business growth. We remain committed to delivering cutting-edge solutions that prioritize public health and safety while providing tangible value to our customers and stakeholders," commented Dr. Rahul Kushwah, COO of Predictmedix.
Predicate Medix首席運營官Rahul Kushwah博士評論道:“我們很高興成功完成了我們的私募,這突顯了我們從投資者那裡獲得的信心和支持。這筆額外的資本將推動我們持續努力,通過人工智慧的力量來革新健康篩查。有了這些資金,我們將進一步開發我們的技術,擴大我們的業務,並推動業務增長。我們將繼續致力於提供領先的解決方案,將公共健康和安全放在首位,同時為我們的客戶和利益相關者提供有形的價值,”Predictic Medix的首席運營官Rahul Kushwah博士評論道。
About Predictmedix Inc.
關於Predicate Medix Inc.
Predictmedix (CSE:PMED) (OTCQB:PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.
普瑞醫療(CSE:PMEd)(OTCQB:PMEDF)(法蘭克福機場:3QP)是一家新興的全球快速健康篩查和遠端患者護理解決方案提供商。該公司的安全入口站由專有人工智慧(AI)提供支持,使用多光譜相機分析生理數據模式並預測各種健康問題,包括傳染病(如新冠肺炎)、藥物或酒精損害、疲勞或各種精神疾病。PredidicMedix專有的遠端患者護理平臺為醫療專業人員提供了一套人工智慧支持的工具,以改善患者的健康狀況。要了解更多資訊,請訪問我們的網站,或在Twitter、Instagram或LinkedIn上關注我們。
Public Relations Contact
公共關係聯繫人
For further media information or to set up an interview, please contact:
欲瞭解更多媒體資訊或安排採訪,請聯繫:
Nelson Hudes
Hudes Communications International
(905) 660 9155
Nelson@hudescommunications.com
納爾遜·胡德斯
哈迪斯國際通信公司
(905)660 9155
郵箱:nelson@hudesCommunication ations.com
Dr. Rahul Kushwah
(647) 889 6916
拉胡爾·庫什瓦博士
(647)889 6916
Caution Regarding Forward-Looking Information:
有關前瞻性資訊的警告:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
本新聞稿可能包含基於當前預期的前瞻性陳述和資訊。這些聲明不應被解讀為對公司未來業績或結果的保證。這類陳述涉及已知和未知的風險、不確定因素和其他因素,可能導致實際結果、業績或成就與這類陳述所暗示的大不相同。雖然這些陳述是基於管理層的合理假設,但不能保證這些假設將被證明是正確的。我們不承擔更新或修改它們以反映新事件或新情況的責任。本公司的證券尚未根據修訂後的《1933年美國證券法》(下稱《美國證券法》)或適用的州證券法進行註冊,除非進行註冊或獲得適用的豁免,否則不得向美國境內的人或美國人提供或出售,或為美國境內的人或“美國人”的賬戶或為他們的利益服務。本新聞稿不應構成出售要約或徵求購買要約,也不應在美國或任何司法管轄區出售任何此類要約、徵求或出售將是非法的證券。此外,存在已知和未知的風險因素,可能導致公司的實際結果、業績或成就與本文包含的前瞻性資訊明示或暗示的未來結果、業績或成就的第4頁存在實質性差異,這些風險因素包括但不限於對獲得監管部門批准的依賴;獲得與其技術相關的知識產權的能力;有限的經營歷史;一般的商業、經濟、競爭、政治、監管和社會不確定性,尤其是與新冠肺炎相關的不確定性;與公司無法控制的因素相關的風險,包括與新冠肺炎相關的風險;與公司股票相關的風險,包括可能或可能不在該方控制範圍內的事件導致的價格波動;對管理層的依賴;以及行業中更多競爭對手的緊急情況。
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
本文中的所有前瞻性資訊都受本警示聲明的約束,公司沒有義務修改或更新任何此類前瞻性資訊,也沒有義務公開宣佈對本文中包含的任何前瞻性資訊的任何修改結果,以反映未來的結果、事件或發展,除非法律要求。
Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."
免責聲明:“本公司目前不會明示或暗示其產品有能力診斷、消除、治癒或控制新冠肺炎(或SARS-2冠狀病毒)。”
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
加拿大證券交易所尚未對本新聞稿的充分性或準確性進行審查,也不承擔任何責任。
SOURCE: PredictMedix Inc.
資料來源:PredidicMedex Inc.